ReviewCureus2026
Repositioning Tradition: A Narrative Review and Expert Opinion on the Clinical Positioning of Glimepiride and Metformin in Nepal's Type 2 Diabetes Mellitus (T2DM) Landscape.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of type 2 diabetes mellitus (T2DM) is rising in Nepal, making the glimepiride-metformin fixed-dose combination (FDC) a commonly used treatment due to its complementary mechanisms of action, effectiveness, and cost-efficiency. This expert opinion aims to identify diverse patient populations most likely to benefit from this combination and guide evidence-based, individualized diabetes management in Nepal. An expert advisory panel consisting of nine clinicians from Nepal convened across two meetings (held in February and March 2025) to share their perspectives on the glimepiride and metformin FDC. Their insights were based on real-world practice patterns, treatment challenges, and local prescribing dynamics to develop clinically relevant recommendations. The expert panel discussions, supported by clinical data, demonstrated that the glimepiride-metformin FDC is a widely used, effective, and affordable option for managing T2DM. It is particularly beneficial for patients requiring rapid glycemic control, those recently diagnosed, and individuals in resource-limited settings. The FDC was found to provide significant glycated hemoglobin (HbA1c) reductions, tolerability at low doses, and improved treatment adherence due to its simplified regimen. While challenges such as the risk of hypoglycemia, weight gain, and limited formulation availability persist, the combination remains a preferred choice in settings where cost and availability are critical concerns. The panel emphasized the importance of individualized dose titration and regular follow-up to optimize outcomes. The glimepiride and metformin FDC continue to be a clinically effective, affordable, and widely applicable treatment option for T2DM in Nepal, particularly suited to meet the needs of diverse patient populations, specifically in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.